Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Shares of global brewer Molson Coors Brewing Co ( TAP - Analyst Report ) recently hit a 52-week high of $47.39 on Mar 8, on the back of solid fourth-quarter 2012 results announced on Feb 14. This Zacks Rank #2 (Buy) company beat its previous 52-week high of $46.50 achieved on Feb 22, and has generated an impressive return of approximately 9.6% since Dec 31, 2012. The company’s long-term estimated EPS growth rate is 5.40%. Average volume of shares traded over the last three months came in at approximately 1,596K.
Impressive Fourth Quarter Results
Molson Coors reported impressive fourth-quarter results beating the Zacks Consensus Estimate for earnings, while lagging that for sales. In fact, Molson Coors has surpassed the Zacks Consensus Estimate in the last five quarters, with an average surprise of 14.2%.
The addition of the Central European operations in the reported results boosted net sales growth by 9.9% to $1.03 billion in the quarter. Increased worldwide beer volume and foreign exchange also impacted the quarter favorably.
We believe that the company’s acquisition of the StarBev business in Jun 2012 significantly enhanced the company’s portfolio of premium brands. It has also created opportunities for the company in Central Europe to extend its key brands, taking advantage of the attractive beer market.
We are encouraged by the company’s strong brand portfolio. In addition, Molson Coors continues to focus on its strategy of maximizing profitable growth opportunities in the core markets and expanding into new and emerging markets. The company is also undertaking restructuring initiatives to reduce overhead costs and boost profitability.
Other Stocks to Consider
Apart from Molson Coors, other stocks in the consumer staples sector that are worth considering are Tyson Foods Inc ( TSN - Analyst Report ) , Kellogg Co. ( K - Analyst Report ) and Hillshire Brands Co. ( HSH - Snapshot Report ) . Hillshire holds a Zacks Rank #1 (Strong Buy), while Kellogg and Tyson carry a Zacks Rank #2 (Buy).
Read the full reports :
Analyst Report on TSN
Analyst Report on TAP
Analyst Report on K
Snapshot Report on HSH